DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
20 hedge funds and large institutions have $5.65M invested in DMK Pharmaceuticals Corporation Common Stock in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 8 closing their positions.
550% more call options, than puts
Call options by funds: $65K | Put options by funds: $10K
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
47% less capital invested
Capital invested by funds: $10.6M → $5.65M (-$4.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
Grow Partners
San Diego,
California
|
+$1.01M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$370K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$131K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$122K |
| 5 |
Goldman Sachs
New York
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$3.34M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$795K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$386K |
| 4 |
SM
Scoggin Management
New York
|
-$349K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$343K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| – | -$3K | -6 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | +$393 | +1 | New |
|
DMK Hedge Fund Activity: Q2 2014 in Review
20 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2014, worth a combined $5.65M — down 47% from $10.6M a quarter earlier.
Fund positioning in DMK was balanced in Q2 2014: 8 funds opened new positions, 8 closed out, 8 added to existing stakes and 2 trimmed.
The largest buyer was Grow Partners, adding an estimated $1.01M. The largest seller was Austin W. Marxe & David M. Greenhouse, exiting entirely with an estimated $3.34M sold.
- 20 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $5.65M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2014, down 47% quarter-over-quarter.
- 8 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2014 and 8 closed out, a net change of 0 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2014 was Grow Partners, an estimated $1.01M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $3.34M sold.
Based on aggregated 13F filings for Q2 2014.